BACKGROUND: The RTS,S/AS01 METHODS: In this observational study, we included children and infants from six African countries (Burkina Faso, Gabon, Ghana, Kenya, Mozambique, and Tanzania) enrolled in the MAL067 immunology ancillary study of the RTS,S/AS01 FINDINGS: We included 718 comparator-vaccinated infants (348 [48%]) and children (370 [52%]) and 606 RTS,S/AS01 INTERPRETATION: Interference between passive immunity and vaccine response is clinically significant and might affect the implementation of next-generation CSP-based vaccines for young infants and mothers as well as passive immunisation with human monoclonal antibodies. FUNDING: US National Institutes of Health, National Institute of Allergy and Infectious Diseases
PATH-Malaria Vaccine Initiative
Spanish Ministerio de Economía y Competitividad (Instituto de Salud Carlos III), European Regional Development Fund and European Social Fund
Fundación Ramón Areces
Spanish Ministry of Science and Innovation
and Generalitat de Catalunya (CERCA Program).